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ABSTRACT The development and usage of safe cell systems for testing agents which possess anti-HIV activity is a 
very important factor in the design of new drugs. We have described in detail a system we designed that is based 
on lentiviral vectors (Prokofjeva et. al., Antiviral Therapy, in print) for  swift and completely safe screening of 
potential HIV-1 replication inhibitors. The system enables one to test the efficiency of the inhibitory activity 
of compounds whose action is directed towards either wild-type HIV-1 reverse transcriptase or integrase, or 
mutant enzymes corresponding to the drug-resistant virus form. Testing results of  a number of already known 
drugs, which correlate well with published data as well as data on newly synthesized compounds, were obtained. 
Application of this system substantially broadens the possibilities of preclinical anti-HIV drugs testing.
KEYWORDS HIV; lentiviral vectors; pseudo-HIV-1 particles; nucleoside reverse transcriptase inhibitors; non-
nucleoside reverse transcriptase inhibitors; integrase inhibitors.
ABBREVIATIONS HIV – human immunodeficiency virus; RT – reverse transcriptase; VSV – vesicular stomatitis 
virus; eGFP – enhanced green fluorescent protein; AZT – 3-azido-3- deoxythymidine; IC50 – half maximal (50%) 
inhibitory concentration (IC) of a substance.
INTRODUCTION
the human immunodeficiency virus type 1 (HIV-1), 
which belongs to the lentivirus genus of the retrovirus 
family, is responsible for one of the most common and 
life-threatening diseases known as the acquired im-
munodeficiency syndrome (AIDS). According to  the 
World Health Organization (WHO), by the end of 2008, 
the number of HIV-1-infected people topped 33 million 
[1]. In 2010,  official records put the number of HIV-1-
infected people in russia at 520,000  [2]. It should be 
noted that in reality the actual number of infected peo-
ple can be two or even three times higher. It follows 
from the prognoses of the WHO and non-governmental 
organizations that even if all the initiatives to control 
AIDS propagation were implemented and anti-HIV 
therapy was used, the number of HIV-infected people 
may still exceed 48 million in the next several years.
Despite great efforts, no efficacious preventive or 
therapeutic vaccine has as yet been designed. the use 
of low-molecular inhibitors of different stages of the 
replicative cycle of the virus remains the only thera-
peutic approach upon HIV infection. thus far, approxi-
mately 30 substances of varying structures have been 
designed and certified as anti-HIV drugs. the majority 
of these substances inhibit three HIV-1 enzymes: re-
verse transcriptase (rt), integrase, and protease; the 
so-called fusion blockers (blocker of viral penetration 
into the cell) were recently  added to this list [3]. the 
simultaneous use of several substances of different 
types in cases of highly active antiretroviral therapy 
(HAArt) enables to achieve a relatively long-term and 
noticeable decrease in virus titer in the blood; hence, a 
patient’s life is prolonged considerably [4, 5]. neverthe-
less,  all the aforementioned substances have several 
limitations. Firstly, long-term administration of drugs is 
required because of the lifetime HIV infection, result-
ing in the emergence of new mutant forms of the virus, 
which are resistant to the drugs used and can further 
spread in the virus population. As a consequence,  viral 
forms that are insusceptible to one or even all classes 56 | ActA nAturAe |  VOL. 3  № 4 (11)  2011
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of the above-listed anti-HIV-1 drugs have been de-
tected in approximately 10% of the u.S. and european 
patients who had never been exposed to antiretroviral 
therapy [6]. Secondly, the need for long-term therapy 
often increases the possibility of adverse effects from 
antiretroviral agents [7, 8]. thus, the search for new 
compounds with anti-HIV-1 activity is an extreme-
ly important issue in modern virology and medicinal 
chemistry. Moreover, it appears necessary to develop 
new agents that can be both relatively safe for  patients 
and at the same time active towards both the wild-type 
virus and its drug-resistant forms.
An important stage in the development of new 
antiretroviral agents is testing their efficacy. Most 
laboratories involved in the search for new anti-HIV 
agents do not have the opportunity to work directly 
with the infectious replication-competent virus. this 
kind of research, which involves personnel coming into 
direct contact with the natural virus, can be performed 
only in certified laboratories that provide conditions 
that ensure operational safety and have permission to 
deal with class III hazard infectious substances. In this 
regard, the development and use of safe cell systems to 
test antiviral activity is of quite high significance in the 
design process of new therapeutic agents. Lentiviral 
vectors, whose functional activity manifests itself as a 
result of the activity of all HIV-1 enzymes, are of par-
ticular interest for  expeditious  and safe screening of   
potential inhibitors of HIV-1 replication.
Since the early 1980s, vectors based on simple and 
complex retroviruses have been intensively used as 
powerful universal tools, including those for design-
ing efficient transfer systems and for the expression 
of different genes and interfering rnAs in human and 
animal cells both in vitro and in vivo [9–13].
Lentiviral vectors have been used in our laboratory, as 
well as in other laboratories, in order to design safe sys-
tems for the screening of  inhibitors of wild-type HIV-1 
replication [14–18]. these systems are represented by a 
recombinant lentivirus carrying a fragment of the HIV-
1 genome, without the regions that encode virus pep-
tides and contain the gene of a reporter (marker) protein 
(e.g., green fluorescent protein). Moreover, pseudoviral 
particles are composed of the enzymes that are required 
for HIV-1 replication (reverse transcriptase, integrase, 
and protease), which provides the potential to synthe-
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size a DnA copy of this genome, as well as the possibil-
ity to integrate it into the host cell genome via the same 
mechanism as the one at play in the infectious HIV-1. It 
is essential that these pseudo-HIV-1 particles can carry 
coat proteins of HIV-1 or other enveloped viruses (e.g., 
G-protein from vesicular stomatitis virus) on their sur-
face, depending on researchers’ choice. this provides 
the possibility of using certain lines of eukaryotic cells 
(target cells) and  sufficiently high infection efficiency. 
the assembly of HIV-1-like particles occurs in this sys-
tem according to the modified procedure that was devel-
oped for constructing virus-like particles on the basis of 
the murine leukemia virus that is related to HIV-1 [19] 
(Fig. 1). this procedure consists in individual introduc-
tion of plasmids containing a) the gag-pol gene of HIV-1 
that encodes the structural proteins for the formation 
of the capsid of a viral particle and HIV-1 enzymes, b) 
the env gene that encodes glycoproteins of the HIV-1 
envelope or the gene of the envelope protein of another 
virus, and c) antiviral DnA that encodes the recom-
binant rnA genome containing the marker gene of the 
fluorescent protein to the cultivated human embryonic 
kidney cells (the so-called packaging cells). After all the 
components listed are introduced into the packaging 
cells, viral proteins and recombinant rnA ensuring the 
formation of the HIV-1-like particles that are released 
into the environment are synthesized in the aforemen-
tioned cells. the addition of these particles to the target 
cells induces the synthesis of the DnA of a provirus that 
contains a marker gene, whose integration into the tar-
get cell genome renders it capable of fluorescing on the 
recombinant rnA genome in target cells. It should be 
stressed that the use of plasmid DnAs expressing indi-
vidual virus-specific proteins enables to construct any 
variants of pseudo-HIV-1 particles with one or several 
mutations in any enzyme of viral replication which cor-
respond to the drug-resistant HIV-1 strains.
thus far, published investigations still contain an in-
sufficient number of examples of  successful use of these 
systems to study the antiretroviral activity of substances 
that differ in their nature; this makes it unclear just how 
universal the described systems are . In this regard,  our 
study mainly endeavoured to verify the adequacy of the 
cell system proposed for screening  potential anti-HIV-1 
agents. the activity of a number of inhibitors of HIV-1 
reverse transcriptase and integrase were tested, both of 
which have found application in medical practice and 
have undergone various stages of laboratory research.
EXPERIMENTAL
Cell cultivation
the following cell lines were used in this study: 
HeK293 (human embryonic kidney cells), Sc-1 (mouse 
embryonic fibroblasts), Jurkat (human t-lymphob-
lastic leukemia), ceM-SS (human t-lymphoblastic 
leukemia), and Kasumi-1 (human acute myeloid leuke-
mia). the HeK293 and Sc-1 cell lines were cultured in 
DMeM containing 10% fetal calf serum (FcS), 4 mM 
of L-glutamine, 100 u/ml of penicillin, and 100 µg/ml 
of streptomycin. the Jurkat, ceM-SS, and Kasumi-1 
cell lines were cultured in rPMI-1640 containing 20% 
FcS, 4 mM of L-glutamine, 100 u/ml of penicillin, and 
100 µg/ml of streptomycin. the cells were grown at 
37°С in humid air containing 5% of СО2.
Obtainment of pseudo-HIV-1 particles
HeK293 cells seeded in Petri dishes with a diameter 
of 100 mm in the amount of 3.0–3.5 × 106 cells per dish 
12–14 h prior to the transfection onset were used as 
packaging cells, in which the assembly of recombinant 
lentiviral (pseudo-HIV-1) particles occurs.
DnA of the lentiviral vector containing the marker 
gene of green fluorescent protein (GFP) and the plas-
mids directing the synthesis of the proteins that are 
required for the formation of pseudo-HIV-1 particles 
were introduced into HeK293 cells via calcium phos-
phate transfection. the infectious pseudo-HIV-1 par-
ticles were collected 24 h following transfection with a 
12 h interval [13].
the virus was titrated on HeK293 cells seeded to 
24-well plates 24 h prior to infection. the level of cell 
fluorescence was measured on an epics 4XL Beckman 
coulter flow cytofluorimeter (uSA) 48 h following the in-
fection. the virus titer was calculated using the formula 
T = NP/V, where N is the amount of seeded cells, P is the 
share of the infected cells in the population, V is the 
amount of the added supernatant containing pseudo-
HIV-1 particles, and T is virus titer. the samples with 
virus titer of 5 × 05–5 × 106 were used in this study.
Investigation of the viral activity of compounds
In order to assess the anti-HIV-1 activity, a solution of 
the analyzed substances in water or dimethylsulfoxide 
(DMSO, the final concentration in the medium was no 
higher than 0.1%), was added to the cells; after 2–8 h 
(depending on the inhibitor), the cells were infected 
with pseudo-HIV-1 particles. the relative level of in-
fection was determined by flow cytofluorimetry on an 
epics 4XL Beckman coulter instrument (uSA) 48 h fol-
lowing the infection.
RESULTS AND DISCUSSION
Construction of pseudo-HIV-1 particles and using 
them to infect different eukaryotic cell lines
efficiency of  transduction of target cells with pseudo-
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resulting transgenic cells, is the most significant pa-
rameter of a lentiviral system. this parameter depends 
on the structure of pseudoviral particles (the type of 
coat proteins) and the particular line of  infected target 
cells. the transplantable human lymphoblastic cells Ju-
rkat and ceM-SS (t-lymphoblastic leukemia contain 
specific HIV-1 receptors), Kasumi-1 (acute myeloid 
leukemia), and mouse embryonic fibroblasts Sc-1 were 
used as target cells.
two types of pseudo-HIV-1 particles differing in 
coat proteins were obtained and subjected to study.   
Particles of the first type contain the HIV-1 coat pro-
tein gp160 (Sugp120 + tMgp41); particles of the sec-
ond type contain the vesicular stomatitis virus (VSV) G 
protein. the use of  particles of the first type resulted 
in a comparatively low transduction efficiency and a 
weaker fluorescence signal (the data are not presented) 
from the infected cells (Fig. 2). In the case of pseudo-
HIV-1 particles carrying the VSV G protein, the share 
of  infected cells and the level of expression of the green 
fluorescent marker protein (eGFP) were considerably 
higher (Fig. 2). Moreover, the particles pseudo-typed 
with the VSV G protein can be used to transfer marker 
genes to the cells with wide type and tissue specificity. 
this procedure enables one to perform the search for 
retroviruses affecting tissues other than blood. there-
fore,  pseudo-HIV-1 particles with the VSV G protein   
were the ones used in most experiments devoted to the 
study of the properties of  inhibitors of HIV-1 reverse 
transcriptase and integrase.
Nucleoside inhibitors of HIV-1 reverse transcriptase
Modified nucleosides and nucleotides have found broad 
application in the therapy of various viral diseases, in-
cluding the HIV-1 infection [3]. their mechanism of   
action includes  conversion of these compounds, in a 
cell, into the corresponding nucleoside triphosphates, 
which act as terminating substrates for viral DnA and 
rnA polymerases. the integration of nucleotides into 
the growing chain of  viral DnA/rnA blocks viral rep-
lication and slows the spread of the infection. the first 
and most well-known anti-HIV-1 agent of this class is 
3’-azido-3’-deoxythymidine (AZt), which can inhibit 
viral replication even at a nano-molar concentration. 
the antiviral activity of AZt was studied with respect 
to pseudo-HIV-1 particles carrying the HIV-1 coat 
protein gp160 or the VSV protein G on their surface. 
Figure 3 shows the effect of AZt on the efficiency of 
cell transduction with HIV-1-like particles containing 
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Fig. 2. The level of transduction of the Jurkat cell line with 
pseudo-HIV-1 particles containing glycoprotein gp160  
of HIV-1 or glycoprotein G of the vesicular stomatitis virus 
(VSV-G) as an envelope protein.
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Fig. 3. The action of AZT on the transduction efficiency of different cell lines with pseudo-HIV-1 particles containing the 
envelope protein gp160 (A), or the envelope protein VSV-G (B). The level of transduction is shown with respect to the 
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reverse transcriptase, wild-type integrase, and HIV-1 
coat protein gp160 (A) or the vesicular stomatitis virus 
G protein (B). It is clear that AZt suppresses the infec-
tion of eukaryotic cells with both types of pseudoviral 
particles, although the concentration of the particles is 
higher than that of infectious HIV-1 (table) [20–22]. 
In the Jurkat cell culture, the activity of the agent was 
higher with respect to the particles pseudotyped with 
the VSV G protein. the antiviral activity of the nucle-
oside  depended not only on the particle type, but also 
on the line of target cells. thus, the maximum effect 
was observed on mouse Sc-1 fibroblasts, whereas the 
minimum effect was observed when using ceM-SS 
cells. the reasons for these differences may be  due to 
the different intracellular contents of nucleoside and 
nucleotide kinases [30], i.e., the enzymes required for 
the conversion of a nucleoside into the corresponding 
triphosphate, and the differences in the levels of ex-
pression of the specific transporters that are respon-
sible for the transport of an agent into the cell, or its 
elimination [31].
Other well-known and commonly used antiretro-
viral agents are 2’,3’-dideoxy-3’-thiocytidine (3tc) 
and 2’,3’-2’,3’-didehydrothymidine (d4t); similar to 
AZt, they are nucleoside inhibitors of HIV-1 reverse 
transcriptase [3]. 3tc was synthesized in 1989 and cer-
tified for clinical use in 1995. It is currently being used 
in combination with other drugs. the efficiency of 
joint use of 3tc and AZt has been demonstrated. We 
assessed the antiviral activity of 3tc on Jurkat and 
ceM-SS cell lines (Fig. 4). Drug activity in our system 
was somewhat lower than  recorded in published data 
[20, 24]. the activity of other nucleoside analogues, 
including d4t, was also lower for our system, in com-
parison with that shown for infectious HIV-1 (Table) 
[20, 21, 24].
Non-nucleoside inhibitors  
of HIV-1 reverse transcriptase
nevirapine is the most commonly used non-nucleoside 
blocker of HIV-1 replication and reverse transcriptase 
inhibitor [3]. this compound was certified as a drug in 
Antiviral activity of the investigated agents with respect to pseudo-HIV-1 particles pseudotyped with vesicular stomati-
tis virus G protein
Agent cell line
ID50, µm
experimental data Published data [20–29]
AZt
Jurkat 0.1 ± 0.01
0.004–0.1
Sc-1 0.08 ± 0.005
Kasumi-1 0.3 ± 0.02
ceM-SS 0.46 ± 0.05
3tc
Jurkat 0.7 ± 0.05
0.02–0.35
ceM-SS 0.85 ± 0.05
d4t
Jurkat 7 ± 0.5
0.43–1.67
Sc-1 10 ± 0.5
ddc
Jurkat 7 ± 0.5
0.067–0.316
Sc-1 5 ± 0.5
ddI
Jurkat > 20
1.79–12
Sc-1 > 20
nevirapine
Jurkat 0.1 ± 0.005
0.0072–0.22
Sc-1 0.15 ± 0.005
Kasumi-1 0.08 ± 0.005
ceM-SS 0.2 ± 0.01
non-nucleoside inhibitor of rt 1 Jurkat 0.95 ± 0.005 0.13
non-nucleoside inhibitor of rt 2 Jurkat 0.08 ± 0.001 0.016
non-nucleoside inhibitor of rt 3 Jurkat 0.085 ± 0.001 0.018
raltegravir
Jurkat 0.009 ± 0.0005
0.0022–0.0037 Sc-1 0.006 ± 0.0005
ceM-SS 0.009 ± 0.0005
L-731988
Jurkat 12 ± 0.1
1
Sc-1 8 ± 0.160 | ActA nAturAe |  VOL. 3  № 4 (11)  2011
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1996; at a concentration of 10-8–10-7 М, it  can slow the 
development of the HIV-1 infection in  cells infected 
with the natural virus. We studied the ability of nevi-
rapine to prevent the transduction of target cells using 
the above-described pseudo-HIV-1 particles. In  similar 
fashion to AZt, nevirapine exhibited a higher antivi-
ral activity towards pseudoviral particles carrying the 
VSV G protein on their surface (Fig. 5). Again, similarly 
to AZt, nevirapine was most efficient in the Sc-1 fi-
broblast culture, and  less efficient in the ceM-SS cell 
line. It should be emphasized that nevirapine activity 
in our system was comparable to its activity towards   
infectious HIV-1 [21, 25].
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Fig. 4. The action of 3TC on the transduction efficiency of 
the cell lines Jurkat and CEM-SS with pseudo-HIV-1 parti-
cles containing the envelope protein VSV-G. The level of 
transduction is shown with respect to the positive control.
In addition to the commercially available drug ne-
virapine, we tested three non-nucleoside inhibitors 
(denoted with the numbers 1, 2, and 3) which were 
synthesized according to the procedure described in 
[27]. these compounds are n1-substituted uracils car-
rying benzophenone-oxyethyl (2 and 3) or benzyl-phe-
noxyethyl fragments (1). these compounds have been 
shown to possess high levels of anti-HIV-1 activity in a 
cell culture infected with the wild-type virus [27]. It was 
demonstrated that all three compounds can prevent the 
transduction of Sc-1 cells with pseudo-HIV-1 particles 
with the VSV G protein; the activity of benzophenone-
containing compounds (2 and 3) was considerably higher 
than that of the benzyl-phenoxyethyl-uracil derivative 
(1) (Fig. 6) and was comparable to that  of nevirapine. 
the data obtained are in good correlation with the re-
sults of the study of these compounds in the infectious 
cell system (Table).
HIV-1 integrase inhibitors
the commercially available drug raltegravir (certified 
for use in clinical practice in October 2007) and the well-
known integrase inhibitor L-731988 were used to assess 
the potential of the designed system for screening in-
tegrase inhibitors [28]. raltegravir and L-731988 block 
the second integration stage, the chain transfer, thus 
impeding integrase binding to cell DnA. the efficiency 
of cell transduction with pseudo-HIV-1 particles with 
wild-type integrase as a function of inhibitor concentra-
tion is shown in Fig. 7. It is clear that  raltegravir activ-
ity is higher than that of L-731988 by approximately 
three orders of magnitude, a fact that correlates with 
the data obtained for the infectious system [28, 32]. A 
decrease in the amount of fluorescing cells in the pres-
ence of integrase inhibitors attests to the fact that an 
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Fig. 5. The action of nevirapine on the transduction efficiency of different cell lines with pseudo-HIV-1 particles containing 
the envelope protein gp160 (A) or envelope protein VSV-G (B). The level of transduction is shown with respect to the 
positive control.reSeArcH ArtIcLeS
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adequate integration of the synthesized DnA into the 
target cell genome takes place in the proposed pseu-
doviral system, and that pseudo-HIV-1 particles can 
indeed be used as a convenient tool for studying the 
antiviral activity of inhibitors of  virus protease.
AZT-resistant pseudo-HIV-1 particles
the search for potential inhibitors of the replication 
of drug-resistant HIV-1 strains is a very important 
task. However, such studies are often hampered not 
only by the need to use an infectious virus that is dan-
gerous for both  personnel and the laboratory, but 
also by the complexity of obtaining strains that would 
be insensitive to this group of preparations. the pro-
posed system allows one to easily construct  variants 
of pseudo-HIV-1 particles that carry replication en-
zymes with the mutations determining their resistance 
to drugs. this fact was verified by constructing three 
types of pseudo-HIV-1 particles with the point sub-
stitutions D67n, K70r, t215F, and K219Q in reverse 
transcriptase, which are most typical of AZt-resistant 
HIV-1 strains [33, 34]. the antiviral activity of AZt was 
compared with that of these variants of pseudo-viral 
particles, demonstrating that AZt had a much weaker 
effect on the efficiency of transduction with mutant 
particles (Fig. 8). the decrease in the inhibiting effect 
correlated with an increase in the number of mutations 
(this effect was most clearly pronounced in Sc-1 cells). 
Meanwhile, nevirapine, the non-nucleoside inhibitor of 
HIV-1 reverse transcriptase, retained its degree of ac-
tivity towards all AZt-resistant types of pseudoviral 
particles (Fig. 9). this can be explained by the fact that 
the site of the binding to AZt is distant from the active 
site of the enzyme, which interacts with  AZt triphos-
phate and contains all the aforementioned mutations. 
thus, it is indeed pseudo-HIV-1 particles that allow one 
to study the ability of a substance to inhibit the drug-
resistant forms of the virus.
Analogues of inorganic pyrophosphate
Another direction in approaches to the therapy of 
drug-resistant forms of HIV-1 consists in searching for   
compounds that would result in the recovery of virus 
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Fig. 7. The action of 
HIV-1 integrase inhibitors 
raltegravir (main figure) 
and L-731988 (inset) on 
the transduction efficiency 
of different cell lines with 
pseudo-HIV-1 particles 
containing the envelope 
protein VSV-G. The level 
of transduction is shown 
with respect to the posi-
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sensitivity to the earlier used antiretroviral agents, 
when used in conjunction with such agents.  the mod-
ern concept holds that HIV-1 resistance to nucleoside 
reverse-transcriptase inhibitors can be achieved us-
ing two alternative mechanisms, which include the 
emergence of the following mutations in reverse tran-
scriptase:
a) Mutations impeding the interaction between the 
enzyme and the corresponding nucleoside triphos-
phates (was described for 3tc) or:
b) Mutations facilitating the cleavage of the already-
integrated terminating nucleotide from DnA during the 
pyrophosphorolysis reaction; after which  synthesis of 
the growing DnA strand can  continue (this mechanism 
is considered to be the major one for AZt) (Fig. 10).
thus far, a number of mimetic compounds of inor-
ganic pyrophosphate capable of suppressing nucleotide 
cleavage upon pyrophosphorolysis have been described 
[35, 36]. One of these, foscarnet (PFA), has been suc-
cessfully used in combination with AZt [37], a fact that 
supports the potential use of non-hydrolysable ana-
logues of inorganic pyrophosphate in combination with 
nucleoside inhibitors in anti-AIDS therapy [37].
Derivatives of the hydroxymethylene diphosphonic 
acid, which are used in the therapy of bone-related 
diseases, are considered to be the most promising 
types of analogues of inorganic pyrophosphate. con-
trary to foscarnet, this class of compounds do not be-
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have as substrates in the pyrophosphorolysis reaction. 
nevertheless, they efficiently inhibit the pyrophos-
phorolytic cleavage of AZt from DnA, which is cata-
lyzed by HIV-1 reverse transcriptase [36]. It should 
also be noted that no data on their activity in cell 
systems have been published. In this study, foscar-
net (PFA) and the analogue of inorganic pyrophos-
phate, biphosphonate 4, were selected to assess the 
adequacy of the proposed cell system and study this 
type of compounds. Among its analogues, the dichlo-
robenzyl derivative of methylene diphosphonic acid 4 
is the most active; it can suppress the cleavage of AZt 
monophosphate catalyzed by reverse transcriptase in 
the submicromolar concentration range [35]. the data 
on the joint action of azidothymine and the specified 
pyrophosphorolysis inhibitors are shown in Fig. 11. 
the degree of cell transduction inhibition with AZt-
resistant pseudo-HIV-1 particles (carrying the point 
substitutions D67n, K70r, t215F, and K219Q in the 
reverse transcriptase) after the introduction of AZt 
combined with the selected pyrophosphorolysis inhib-
itor was determined in this experiment. the quantity 
of fluorescing cells in the individual presence of each 
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of these substances  was determined in the control ex-
periment.
A conclusion concerning the additivity of the ac-
tion of AZt and pyrophosphate analogues was made 
by comparing the degree of inhibition in the presence 
of two substances and the product of the degrees of 
inhibition by each substance (which attests to the in-
dependence of their action). As can be seen in Fig. 11, 
foscarnet and biphosphonate 4 suppressed cell infection 
with pseudoviral particles and provided a considerable 
and statistically significant enhancement of the action 
of AZt. thus, the data obtained  demonstrate, for the 
first time, that it is  possible to recover the sensitiv-
ity of  resistant forms of HIV-1 to nucleoside reverse 
transcriptase inhibitors in a cell culture. the data is 
also testament to the fact that analogues of inorganic 
pyrophosphate are promising agents for antiretroviral 
therapy.
CONCLUSIONS
A number of human and mouse cell lines were used to 
demonstrate that the described system for safe screen-
ing of potential HIV-1 replication inhibitors allows 
one to test the inhibitory activity of the compounds, 
whose action is directed both towards the reverse tran-
scriptase and integrase of wild-type HIV-1 and towards 
their mutant forms corresponding to drug-resistant 
forms of the virus. It is important that the pseudo-
HIV-1 particles used in this system are noninfectious. 
they are actually single-acting viruses (recombinant 
lentiviral vectors) that contain a complete set of viral 
enzymes ensuring the synthesis of the recombinant 
two-stranded DnA provirus and its integration into 
the genome of target cells. next, the cell systems allow   
the expression of marker genes, which were integrated 
into the cell genome, within the recombinant genome of 
pseudo-HIV-1 particles.
the absence of a complete set of HIV-1 in this re-
combinant genome on one hand ensures  safety when 
testing the efficacy of new anti-HIV-1 compounds and, 
on the other hand, enables to adequately assess the ac-
tion of these compounds on HIV-1 reverse transcriptase 
and integrase in the cells infected (transduced) with 
pseudo-HIV-1 particles. the possibility of forming 
pseudo-HIV-1 particles containing mutant drug-re-
sistant reverse transcriptase and/or integrase allows 
one to perform the screening of potential inhibitors of 
drug-resistant forms of HIV-1.
Pseudotyping of a pseudo-HIV-1 particle with coat 
proteins of retroviruses of a different nature (includ-
ing HIV-1 coat protein gp160) and those of other envel-
oped viruses considerably broadens the possibilities of 
the screening system by enabling the infection of cells 
of different types, and it also enables testing of the in-
hibitors of virus penetration into the cell. Finally, this 
system allows one to study the HIV-1 protease inhibi-
tors, although this was beyond the scope of the present 
work. 
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